Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

Open access
Ritzel, R., Roussel, R., Bolli, G. B., Vinet, L., Brulle‐Wohlhueter, C., Glezer, S., Yki‐Järvinen, H. · 2015 · Diabetes, Obesity and Metabolism

Abstract

Aims: To conduct a patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies, which compared the efficacy and safety of new insulin glargine 300 U/ml ( G la‐300) with insulin glargine 100 U/ml ( G la‐100) in people with type 2 diabetes ( T2DM ) on basal and mealtime insulin, basal insulin and oral antihyperglycaemic drugs, or no prior insulin, respectively. Methods: The EDITION studies were multicentre, randomized, open‐label, parallel‐group, phase IIIa studies, with similar designs and endpoints. A patient‐level meta‐analysis of the studies enabled these endpoints to be examined over 6 months in a large population with T2DM ( G la‐300, n = 1247; G la‐100, n = 1249). Results: No significant study‐by‐treatment interactions across studies were found, enabling them to be pooled. The mean change in glycated haemoglobin was comparable for G la‐300 and G la‐100 [each −1.02 (standard error 0.03)%; least squares ( LS ) mean difference 0.00 (95% confidence interval (CI) −0.08 to 0.07)%]. Annualized rates of confirmed (≤3.9 mmol/l) or severe hypoglycaemia were lower with G la‐300 than with G la‐100 during the night (31% difference in rate ratio over 6 months) and at any time (24 h, 14% difference). Consistent reductions were observed in percentage of participants with ≥1 hypoglycaemic event. Severe hypoglycaemia at any time (24 h) was rare ( G la‐300: 2.3%; G la‐100: 2.6%). Weight gain was low (<1 kg) in both groups, with less gain with G la‐300 [ LS mean difference −0.28 kg (95% CI −0.55 to −0.01); p = 0.039]. Both treatments were well tolerated, with similar rates of adverse events. Conclusion: Gla‐300 provides comparable glycaemic control to G la‐100 in a large population with a broad clinical spectrum of T2DM , with consistently less hypoglycaemia at any time of day and less nocturnal hypoglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12485

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 236

Metadata

Authors
Ritzel, R., Roussel, R., Bolli, G. B., Vinet, L., Brulle‐Wohlhueter, C., Glezer, S., & Yki‐Järvinen, H.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-06-16
Volume
17
Issue
9
Pages
859-867
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1545770620
Cited by
236
References
10
FWCI
28.60
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12485
The paper
Ritzel, R., Roussel, R., Bolli, G. B., Vinet, L., Brulle‐Wohlhueter, C., Glezer, S., & Yki‐Järvinen, H. (2015). Patient‐level meta‐analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12485

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.